{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:51:03Z","timestamp":1768564263994,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This report describes polysomnography and sleep diary exposure\u2013response analyses from Study E2006\u2010G000\u2010304 (Study 304), a 1\u2010month trial of 5\u2010 or 10\u2010mg lemborexant, zolpidem, or placebo; and Study E2006\u2010G000\u2010303 (Study 303), a 6\u2010month trial of 5\u2010 or 10\u2010mg lemborexant or placebo. Studies 304 and 303 included 1006 (86%) and 956 (68%) (female) participants, respectively; &gt;40% were \u226565\u00a0years, with individual lemborexant exposures derived from a previously described pharmacokinetic model. Linear mixed\u2010effects analyses of polysomnography: latency to persistent sleep (LPS), sleep efficiency (SE), and wake after sleep onset (WASO) quantified the change from baseline given lemborexant exposure, time, and covariates, guided by consensus recommendations regarding clinical significance. A small impact of sex, body weight, and race was predicted for LPS and SE, irrespective of treatment. Effect of age on LPS was small; baseline SE was estimated to be 8% higher for a 50\u2010year\u2010old versus an 80\u2010year\u2010old, decreasing to 6% by 1\u00a0month. Baseline WASO\u00a0was 13 minutes longer for Black versus White subjects, corresponding to a 5\u2010minute lower change from baseline at the end of the study. For subjective end points, the statistically significant covariate effects for age, sex, and race were not deemed therapeutically relevant, likely reflecting physiologic sleep pattern changes across age and study subgroups. Both polysomnography and subjective analyses indicated clinically meaningful differences from baseline for both lemborexant treatments, with effects being greater for 10\u2010mg versus 5\u2010mg lemborexant, while indicating that covariate\u2010specific lemborexant dose adjustments are not warranted.<\/jats:p>","DOI":"10.1002\/jcph.2192","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T09:49:49Z","timestamp":1671184189000},"page":"498-511","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exposure\u2013Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia"],"prefix":"10.1002","volume":"63","author":[{"given":"Bojan","family":"Lalovic","sequence":"first","affiliation":[{"name":"Eisai Inc.  Nutley New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishani","family":"Savant Landry","sequence":"additional","affiliation":[{"name":"Eisai Inc.  Nutley New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Moline","sequence":"additional","affiliation":[{"name":"Eisai Inc.  Nutley New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Reyderman","sequence":"additional","affiliation":[{"name":"Eisai Inc.  Nutley New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Hussein","sequence":"additional","affiliation":[{"name":"Eisai Limited  Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"issue":"5","key":"e_1_2_9_2_1","first-page":"e157","article-title":"Healthcare utilization and costs in persons with insomnia in a managed care population","volume":"20","author":"Anderson LH","year":"2014","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz007"},{"issue":"16","key":"e_1_2_9_4_1","first-page":"27","article-title":"Daytime sleepiness and insomnia as correlates of depression","volume":"65","author":"Fava M","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00072-1"},{"key":"e_1_2_9_6_1","volume-title":"Sleep Medicine: A Comprehensive Guide to Its Development, Clinical Milestones, and Advances in Treatment","author":"Billiard M","year":"2015"},{"issue":"4","key":"e_1_2_9_7_1","first-page":"S76","article-title":"Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy","volume":"26","author":"Dopheide JA","year":"2020","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2004.02.010"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2017.09.001"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/27.7.1255"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0474-9"},{"issue":"11","key":"e_1_2_9_12_1","first-page":"759","article-title":"Pharmacological treatment of insomnia","volume":"40","author":"Lie JD","year":"2015","journal-title":"P T"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.014381"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)00058-1"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2005.04981.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81973-X"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70053-5"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.10.003"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00436-1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz076"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01276-1"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18254"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2016.07.002"},{"key":"e_1_2_9_26_1","volume-title":"The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications","author":"Iber C","year":"2007"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6800"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1683"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2014.4816"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6470"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110379307"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855343"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2175"},{"key":"e_1_2_9_34_1","unstructured":"Center for Drug Evaluation and Research.Clinical Pharmacology and Biopharmaceutics Review(s)\u2013Suvorexant.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204569Orig1s000ClinPharmR.pdf. Accessed January 3 2023."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9534-0"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1953"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9148"},{"issue":"2","key":"e_1_2_9_38_1","first-page":"1","article-title":"NIH State\u2010of\u2010the\u2010Science Conference Statement on manifestations and management ofchronic insomnia in adults","volume":"22","year":"2005","journal-title":"NIH Consens State Sci Statements"},{"key":"e_1_2_9_39_1","unstructured":"US Food and Drug Administration.Questions and answers: risk of next\u2010morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien Ambien CR Edluar and Zolpimist).https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/questions\u2010and\u2010answers\u2010risk\u2010next\u2010morning\u2010impairment\u2010after\u2010use\u2010insomnia\u2010drugs\u2010fda\u2010requires\u2010lower. Accessed January 3 2023."},{"key":"e_1_2_9_40_1","unstructured":"BELSOMRA\u00ae(suvorexant) tablets for oral use. Prescribing Information:Merck & Co. Inc.;2014."},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-013-0294-y"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/914168"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.2192","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T05:08:39Z","timestamp":1697087319000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1002\/jcph.2192"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2192","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]},"assertion":[{"value":"2022-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}